The association between the upper and lower airways has been recognised for almost 2000 years. Epidemiological data suggest that most asthma patients also suffer from allergic rhinitis, and that both diseases share similar trigger factors and pathophysiology. This IPCRG Guideline on the management of rhinitis in primary care is fully consistent with the ARIA guidelines. It highlights the treatment goals and the classification of the condition according to symptom frequency (intermittent or persistent) and severity (mild or moderate-severe). It covers the need for allergen avoidance, pharmacologic therapy including immunotherapy, alternative therapies, management of ocular symptoms, the management of coexisting allergic rhinitis and asthma, and the need for follow-up and ongoing care for patients with rhinitis.
are not available. Since clinical management which follows evidence-based guidelines yields better results for patients, it is important to have access to primary care guidelines which are specifically relevant to, and provided by, primary care. The International Primary Care Respiratory Group (IPCRG) asked primary care experts from several countries to develop primary care guidelines for the diagnosis and treatment of asthma, chronic obstructive pulmonary disease (COPD) and rhinitis. A brief summary of the expert report (which took three years to complete) was published as a handbook [1] 
in 2005.
This paper is devoted to the management of rhinitis in primary care and is specifically written for primary care health professionals. In addition to this rhinitis section, the IPCRG guidelines consist of papers on the diagnosis of respiratory disease [2] , and the management of COPD [3] and asthma [4] . For the specific purpose of ranking the evidence in each of these publications, we have used the so-called Three Star System of the Royal College of General Practitioners [5] in order to score the evidence of the statements made (see box).
Introduction
The association between the upper and lower airways has been recognized for almost two millennia, ever since Galen recommended in 200AD that purging the nostrils of secretions would relieve the lungs. By the late 19 th century Charles Blackley had linked hay fever and asthma [6] .
It is therefore striking that until recently asthma guidelines have referred minimally to the importance of rhinitis in patients with asthma. The 1997 UK asthma guidelines did not even mention the word rhinitis [7] . The updated 2003 UK guidelines mention its role in helping to make a diagnosis of asthma, state that immunotherapy for rhinitis sufferers might reduce the rate of onset of asthma, and state that many patients with asthma may have rhinitis but that there is no evidence that rhinitis treatment improves asthma outcomes [8] . In 2002 the Global Initiative for Asthma guidelines (GINA) discussed the same issues as the UK asthma guidelines but also added that treatment of rhinitis may improve asthma outcomes [9] . This major change followed a World Health Organization initiative -publication of Allergic Rhinitis and its Impact on Asthma (ARIA), a comprehensive review of the impact of allergic rhinitis on asthma [10] , and evidence has evolved even further since its publication.
Evidence that influenced guidelines
Asthma and allergic rhinitis (AR) frequently coexist with epidemiological data suggesting that most asthma patients also suffer from allergic rhinitis [11] . We also see similar trends in asthma and AR prevalence around the world using objective epidemiological instruments [12] . Both diseases share similar triggers and similar pathophysiology characterised by similar inflammatory cell infiltrates [13] . It has also been found that the degree of inflammation in asthma correlates highly with the level of inflammation in the nose [13] , that allergen challenge in the nose leads to hyperresponsiveness in the lungs [14] and that allergen challenge in the lung leads to inflammation in the nose [15] . More important than the simple association between asthma and rhinitis is the finding that clinically diagnosed allergic rhinitis is associated with significantly worse asthma control; studies from a recent analysis of patients in a General Practice database in the UK found that children with physician-diagnosed AR were more than twice as likely to be hospitalised for asthma as those without AR, and that adults with AR were 50% more likely be admitted for asthma [16, 17] .
As a result the ARIA guidelines recommend that patients with asthma be evaluated for allergic rhinitis and vice versa. The guidelines support a combined approach to treating both conditions [10] , an approach based on: education and allergen avoidance; pharmacotherapy for allergic rhinitis along with asthma therapy; specific immunotherapy; and rarely surgery.
Treatment Goals
Goals for the treatment of rhinitis assume accurate diagnosis and assessment of severity as well as any link with asthma in an individual patient. Goals include:
• Unimpaired sleep • Ability to undertake normal daily activities, including work and school attendance, without limitation or impairment, and the ability to participate fully in sport and leisure activities • No troublesome symptoms • No or minimal side-effects of rhinitis treatment
Classification
The classification of allergic rhinitis depends on the duration of symptoms (''Intermittent'' or ''Persistent'') together with the severity and effect on the patient's daily life (''Mild'' or ''ModerateSevere'') ( Figure 1 ) [10] . The classification of rhinitis determines the treatment needed. Those with mild disease which is intermittent in nature require less intensive therapy [10] .
Allergen and pollutant avoidance
Whilst removal of allergens lessens the severity of the allergic disorder, it is not always possible to implement fully adequate allergen avoidance; as a result no truly convincing trial results have been achieved [18] . Allergen sensitivity should be documented before recommending avoidance measures that may have considerable lifestyle implications [19] * .
Patients with allergic rhinitis should be advised not to smoke since this may worsen asthma and rhinitis and reduce treatment efficacy, and to limit their exposure to environmental tobacco smoke as much as possible. Pharmacotherapy and support for smoking cessation should be provided when appropriate.
Pharmacologic therapy
Pharmacologic treatment of allergic rhinitis depends on both the classification of severity and the individual patient's symptoms as described in Figure 1 . Table 1 provides treatment options based on the severity of the disease. The choice of pharmacologic treatment may be individualized based on the patient's particular combination of symptoms. Medications for allergic rhinitis have no long-lasting effect following discontinuation. Therefore, in persistent disease, maintenance treatment is required. Table 2 provides detailed notes on the treatments available in rhinitis. • Oral H1-blocker
• Antileukotriene (preferred in patients with coexisting asthma) • Cromone
• Consider specialist referral for specific immunotherapy • Antileukotriene (preferred in patients with coexisting asthma)
Review patient after 2-4 weeks.
• Consider specialist referral for specific immunotherapy • If failure: consider specialist referral (including surgery).
NOTES: Treatment options in the table above are given in increasing order of cost. Relative medication costs may vary from country to country. The choice among treatment options is likely to depend somewhat on local availability of drugs, national formularies, and cost. If administered, patients should be advised of the expected side effects (see Table 2 ) of first-generation oral H1-antihistamines including sedation and central nervous system impairment which can affect performance of cognitive and skilled tasks such as learning and driving [24] *** . These impairments can be potentiated by alcohol and other sedative medications, and can worsen sleep disturbance due to rhinitis. Side-effects may not always be perceived by patients. Some, but not all, oral H 1 -antihistamines undergo hepatic metabolism via the cytochrome P450 system and may be prone to drug interactions. Certain medications, herbal products, foods and dietary supplements, can affect the bioavailability of some second-generation antihistamines. H 1 -antihistamines are approved for use in young children [25] . Major concerns exist about the arrhythmogenic action of terfenadine, astemizole, and high doses of diphenhydramine. This is not a class effect [22] , and the use of terfenadine and astemisole is therefore not advised [10] *** .
H 1 -antihistamines given topically (intranasally or ocularly) are as effective as oral antihistamines at the site of their administration in reducing itching, sneezing, runny nose, and eye symptoms [21, 22, 26] . They can be effective within 20 minutes of administration [27] *** . Topical H 1 -antihistamines require twice-a-day dosing. In general, topical antihistamines are well tolerated.
Intranasal glucocorticosteroids
Intranasal glucocorticosteroids are currently the most effective class of medications available for the treatment of allergic and non-allergic rhinitis [28] . The effectiveness of intranasal glucocorticosteroids is based on their local activity since administration of an equivalent amount of medication orally produces no benefit. The rationale for using intranasal glucocorticosteroids in the treatment of allergic rhinitis is that high medication concentrations can be achieved at receptor sites in the nasal mucosa with minimal risk of systemic adverse effects [10] *** .
Glucocorticosteroids can suppress many stages of the allergic inflammatory process by interacting with transcription factors [29, 30] . Due to their mechanism of action, efficacy appears after 7-8 hours of dosing, but maximum efficacy may require up to two weeks. Intranasal glucocorticosteroids have also been shown to improve quality of life, increase the patient's sense of well-being, improve performance at work and school, and reduce sleep problems associated with nasal congestion [31, 32] In clinical studies, intranasal glucocorticosteroids are well tolerated, and adverse effects are few in number, mild in severity, and similar to placebo [37] . Crusting, dryness and minor epistaxis may occur in about 5% of patients and may be a reason for stopping treatment. Evidence shows that long-term use of intranasal glucocorticosteroids is free of the concerns associated with long-term use of oral glucocorticosteroids. Even with long-term use, newer intranasal glucocorticosteroids appear to have no effect on the hypothalamic-pituitaryadrenal axis and do not induce nasal mucosal atrophy [38] [39] [40] . In children, the rate of growth was slightly reduced in those regularly treated with beclomethasone over one year by the intranasal route [41] . The clinical significance of this reduced rate of growth is unknown. This effect does not appear to be a class effect since recent studies have shown normal growth rates in children treated with newer intranasal glucocorticosteroids [42] . However, it is reasonable to monitor the growth of children receiving long-term treatments with intranasal glucocorticosteroids.
The health care professional should advise patients on the proper method to administer intranasal glucocorticosteroids, including the importance of directing the spray laterally and not medially (towards the nasal septum).
Systemic and intranasal glucocorticosteroids
Oral glucocorticosteroids are rarely needed to control severe symptoms of allergic rhinitis. Although these medications are effective, they cause unacceptable systemic side effects if used for a prolonged period of time. A short course of oral corticosteroids (three to seven days) may be necessary for patients with severe symptoms or to gain control of symptom exacerbations. Intramuscular injection of glucocorticosteroids is not recommended by ARIA due to the possible occurrence of systemic side effects [10] 
Decongestants
Short courses (less than 10 days) of topical decongestants may be useful in reducing severe nasal blockage when starting administration of other medications. Both oral and intranasal decongestants may be used in the treatment of nasal congestion associated with allergic rhinitis. Nasal decongestant sprays have a greater effect on nasal obstruction than oral decongestants. However, the use of nasal decongestant sprays is limited by rebound congestion, the potential for irreversible tissue hypertrophy [43] *** , and a decreasing duration of effect after 10 days of use [44] *** . Rhinitis medicamentosa constitutes nasal hyper-reactivity, mucosal swelling, and tolerance, that is induced, or aggravated, by the overuse of topical decongestants with or without a preservative.
Attention should be paid to a range of possible contraindications and warnings associated with oral decongestants, including use in elderly patients, patients suffering from hypertension, hyperthyroidism, prostatic hypertrophy, glaucoma, and psychiatric disorders, and in patients taking beta-blockers and monoamine oxidase inhibitors [10] *** .
Anticholinergics
Anticholinergic agents can help reduce anterior watery rhinorrhea but they have no effect on nasal blockage or the other symptoms of allergic rhinitis [10] *** .
Antileukotrienes
Antileukotrienes are a new class of medication for the treatment of allergic rhinitis as well as asthma and have been shown to be effective in improving both asthma and rhinitis outcomes [45] 
Allergen-specific immunotherapy (vaccination)
Allergen-specific vaccination is the practice of administering gradually increasing quantities of an allergen extract to an allergic subject in order to ameliorate the symptoms associated with subsequent exposure to the causative allergen. The efficacy of immunotherapy using inhalant allergens to treat allergic rhinitis and asthma is evidence-based when optimally administered [10, 49] *** . Standardised therapeutic vaccines which are available for the most common allergens are favoured. Adequate courses of therapy (three to four years) may induce prolonged remission of symptoms. Treatment is recommended for patients with evidence of clinically relevant IgE-mediated disease and a limited spectrum of allergies, in whom pharmacotherapy and avoidance measures provide inadequate control [10] .
Subcutaneous immunotherapy should be performed by trained personnel supervised by a physician, and patients should be monitored for 30 minutes after injection. Medications and equipment for treatment of rare but potentially life-threatening acute allergic reactions triggered by subcutaneous immunotherapy should be available.
Allergen-specific immunotherapy interferes with the basic mechanisms of allergy and alters the natural course of allergic diseases, resulting in symptomatic relief and offering the patient a long-lasting and preventive effect; it is currently recommended for those patients with moderate to severe disease especially if not responsive to other therapy [10] . Treatment benefits are observed both using subcutaneous [50] and sublingual routes [51] . Subcutaneous immunotherapy has been shown to reduce the onset of new sensitisations [52] as well as the development of asthma in patients with allergic rhinitis [53] .
Alternative therapies
The use of complementary and alternative therapies (e.g. homeopathy, herbal medicines, acupuncture) for the treatment of rhinitis is increasing. In the ARIA document [10] , a literature review found insufficient evidence to support the efficacy of alternative therapy. Since then there have been further publications, but the design of the trials or the outcome measures used make it impossible to reach a definitive conclusion regarding their use in the management of allergic rhinitis. * A recent Cochrane Review concluded that there was insufficient evidence to assess reliably the role of homeopathy in asthma [54] . There is an urgent need for well-designed, large, randomised, controlled and properly-powered clinical trials to evaluate the efficacy and safety of alternative therapies in the management of allergic diseases.
Herbal medicine can induce pharmacologic interactions with medications used in the treatment of allergic rhinitis or other illnesses [55] . Healthcare professionals should ask their patients about the use of herbal products and consider the possibility of herb-drug interactions [56] .
Route of administration
Medications for allergic rhinitis are most commonly given either intranasally or orally. The advantage of intranasal administration, particularly of glucocorticosteroids, is that high local concentrations of the drug can be achieved with minimal systemic side effects [57] *** . The health care professional should advise patients on the proper method to administer intranasal glucocorticosteroids, including the importance of directing the spray laterally rather than medially in the nose, using the left hand for the right side of the nose and vice versa.
Management of ocular symptoms
Intranasal glucocorticosteroids have been shown to have some effect on the eye symptoms associated with allergic rhinitis [58, 59 ,60] *** . Intraocular glucocorticosteroids are effective, but because of known side effects should be avoided or should only be prescribed and monitored by eye specialists. The use of antihistamine or cromone eye drops is justified if ocular symptoms are the predominant and/or persistent feature of the patient's allergic rhinitis despite use of oral H1-antihistamines and/or intranasal glucocorticosteroids. Cold compresses are effective for mild to moderate ocular symptoms, and topical non-steroidal anti-inflammatory drugs (NSAIDs) relieve itching.
Management of co-existing allergic rhinitis and asthma
Allergic rhinitis and asthma often co-exist: at least 75% of patients with asthma complain of rhinitis symptoms, and 20-30% of those with allergic rhinitis also have asthma [61, 62] . Allergic rhinitis is also a risk factor for developing asthma [63] . Recent evidence suggests that patients with coexisting physician-diagnosed asthma and rhinitis have worse asthma outcomes than those with physician-diagnosed asthma only [64, 65] . Thus, patients with asthma should be assessed for symptoms and signs of rhinitis and vice versa.
Some medications (e.g., glucocorticosteroids and antileukotrienes) are effective against both allergic rhinitis and asthma symptoms. Patients with both allergic rhinitis and asthma may be prescribed both intranasal and inhaled glucocorticosteroids if appropriate to the severity of their disease, although attention should be paid to the total dose of glucocorticosteroids, particularly in children. Optimal management of rhinitis may improve co-existing asthma and failure to treat rhinitis adequately in those with asthma may make asthma more difficult to control.
Management of allergic rhinitis during pregnancy
Rhinitis is often a problem during pregnancy, since it can cause exacerbation of nasal obstruction. Caution must be used when administering rhinitis medication during pregnancy because of placental transfer, although in asthmatic patients the benefits of treating asthma outweigh any potential risks to the fetus from inhaled steroids. Few studies on the use of allergic rhinitis medications during pregnancy have been conducted.
Follow-up and Ongoing Care
Patients should be reviewed two to four weeks after initiation of therapy. In general, if patients show improvement then the medication dose should be stepped down if possible. When treating persistent rhinitis, patients should continue treatment for at least one month after resolution of symptoms.
If patients fail to respond to initial therapy, it is essential to review compliance and reconsider the diagnosis, querying infections and other potential causes of symptoms. If there is confidence about the diagnosis, a one-month trial of an alternative therapy is indicated.
Access to professional advice
Many of the treatments referred to in this paper can be accessed 'over the counter' without a prescription from a pharmacy, and some can be obtained from any retail outlet. The exact level of access varies across different countries. In many countries the role of the community pharmacist is becoming more clinical and patientfocused, and ARIA have produced specific guidelines for pharmacists to use when advising patients who seek advice regarding the symptoms of rhinitis [66] .
Referral
Referral should be considered for any patient who shows persistent failure to respond to the therapeutic options for their classification of rhinitis or whose symptoms are suggestive of other conditions (see Allergic Rhinitis Diagnosis Questionnaire, Tables 3 and 4 in the IPCRG Guidelines: Diagnosis [2] ).
Conclusions and recommendations
Rhinitis is an important condition both in its own right and because of its impact on asthma. The aim of treatment should be to ensure as full a quality of life as possible for patients with rhinitis based on education and allergen avoidance, pharmacotherapy, specific immunotherapy and rarely surgery. For patients with both asthma and rhinitis there should be a combined approach to treatment, thereby ensuring best possible control of both conditions.
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